ArticleGeneral thoracic and cardiovascular surgery2026
Prognostic utility of serum albumin in underweight patients who underwent isolated surgical aortic valve replacement.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe clinical impact of underweight on outcomes in patients undergoing surgical aortic valve replacement (SAVR) remains unclear. This study aimed to investigate the prognostic significance of underweight status in patients undergoing SAVR and to identify key determinants of adverse outcomes within this population.
methods805 patients underwent SAVR between January 2016 and December 2021 at eight Japanese centers. After excluding 31 patients with missing laboratory data, a total of 774 patients were included. Patients were categorized into underweight group (Body mass index [BMI] < 18.5 kg/m², 79 patients), normal-weight group (BMI 18.5-25 kg/m², 464 patients), and overweight group (BMI ≥25 kg/m², 231 patients). The primary endpoint was all-cause mortality.
resultsThe median age was 76 years (interquartile range [IQR]: 71-79), and the median BMI was 23.3 kg/m² (IQR: 20.9-25.8). Underweight patients had the highest 5-year mortality, followed by normal-weight and overweight patients (23.5%, 11.9%, and 7.4%; p = 0.001). In multivariable analysis, BMI was an independent predictor of mortality (1.0 kg/m² increase, adjusted hazard ratio: 0.92; 95% confidence interval: 0.86 to 0.99; p = 0.020). Among underweight patients, serum albumin was independently associated with all-cause mortality (p = 0.002). Underweight patients were stratified by median albumin into low (< 4.0 g/dL, n = 43) and normal (≥ 4.0 g/dL, n = 36) groups, and 5-year mortality was higher in the low albumin group (34.1% vs. 12.6%, p = 0.015).
conclusionsLow BMI was associated with higher mortality after SAVR, and serum albumin provided additional risk stratification within underweight group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.